Boehringer Ingelheim Vetmedica Gmbh

Other

Andrea Vollmar

Juergen Daemmgen

Olaf Joens

Rainer Kleemann

Christian Troetschel

A method for treating a patient suffering from ISACHC Classification Class I heart failure includes administering to the patient a therapeutically effective amount of pimobendan or a pharmaceutically acceptable salt thereof, where the administration results in a reduction in the size of the patient's heart.

PDE III inhibitors for treatment of asymptomatic heart failure

Phosphodiesterase type III (PDE III) inhibitor or a 'Ca-sensitizing agent' or a pharmaceutically acceptable derivative thereof is used in the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure, and as a medication for the reverse remodeling of the heart of a patient with asymptomatic (occult) heart failure and their delayed onset of clinical symptoms.

The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure or for the reduction of heart size in patients having symptomatic or asymptomatic (occult) heart failure.

Growing community of inventors

Wissen, Germany

Andrea Vollmar